首页> 外文期刊>ACS medicinal chemistry letters >Synthesis, in Vitro Covalent Binding Evaluation, and Metabolism of ~(14)C-Labeled Inhibitors of 11β-HSD1
【24h】

Synthesis, in Vitro Covalent Binding Evaluation, and Metabolism of ~(14)C-Labeled Inhibitors of 11β-HSD1

机译:11β-HSD1的〜(14)C标签抑制剂的合成,体外共价结合评价和代谢

获取原文
获取原文并翻译 | 示例
           

摘要

In this letter, we reported the design and synthesis of three potent, selective, and orally bioavailable 11β-HSD1 inhibitors labeled with 14C: AMG 456 (1), AM-6949 (2), and AM-7715 (3). We evaluated the covalent protein binding of the labeled inhibitors in human liver microsomes in vitro and assessed their potential bioactivation risk in humans. We then studied the in vitro mechanism of 2 in human hepatocytes and the formation of reactive intermediates. Our study results suggest that 1 and 3 have low potential for metabolic bioactivation in humans, while 2 has relatively high risk.
机译:在这封信中,我们报告了标记为14C的三种有效,选择性和口服可生物利用的11β-HSD1抑制剂的设计和合成:AMG 456(1),AM-6949(2)和AM-7715(3)。我们评估了人类肝微粒体中标记的抑制剂的共价蛋白结合,并评估了其在人类中潜在的生物激活风险。然后,我们研究了人类肝细胞中2的体外机制以及反应性中间体的形成。我们的研究结果表明1和3具有较低的人类代谢生物激活潜力,而2具有较高的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号